Amgen Inc.

Amgen’s 2025 10-K, specifically within the Management’s Discussion and Analysis (MD&A), dedicates attention to the intricacies of its supply chain. Item 7, “Overview,” directly references “Manufacturing difficulties, disruptions or delays” as a potential limiter of product supply and sales. The company’s discussion on “Raw Materials and Medical Devices” highlights a reliance on “unaffiliated third-party suppliers,” noting that certain critical components may originate from a single source. This operational focus suggests a company managing the practicalities of product delivery rather than immediate financial distress.

The usual forensic accounting metrics, designed to detect financial stress or obfuscation, are not available for this filing. The Beneish M-Score, Beneish’s (1999) eight-ratio earnings-manipulation detector, is absent. Similarly, Altman’s Z″ — a 1968 bankruptcy-distress index — is not provided. Piotroski’s F-Score, Piotroski’s (2000) 9-point fundamental strength scan, also remains uncalculated. Finally, the Fog Index, Gunning’s (1952) readability score where 18+ indicates obfuscation, is likewise unavailable. Consequently, this reading must rely solely on the qualitative disclosures presented.

Item 7 elaborates on the company’s reliance on unaffiliated third-party suppliers, certain of which may be our only source for such materials. This concentration risk implies that disruptions from a single vendor could significantly impact Amgen’s ability to produce and sell its products. The company states it works to mitigate this by “inventory management, relationship management and evaluation of alternative sources when feasible.” Furthermore, Amgen monitors the “financial condition and manufacturing quality and compliance of key suppliers,” indicating a proactive approach to managing these critical dependencies.

Without the quantitative signals from the Beneish M-Score, Altman Z″, Piotroski F-Score, or Fog Index, this reading is confined to the qualitative disclosures provided. The filing offers insights into Amgen’s operational risk management, particularly concerning supply chain vulnerabilities. However, it cannot inform on potential earnings manipulation, bankruptcy risk, fundamental financial strength, or the overall readability of the document itself. The absence of these metrics means the filing, as excerpted, does not present immediate red flags, but also offers no strong quantitative indicators of deep value.